Medical Devices Startups

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.

7 investors

Atomic Alchemy developed technology and facilities for producing radioisotopes for medical, industrial, and research applications, planning dedicated isotope-production reactors in Idaho. Acquired by Oklo in 2024.

7 investors

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity. The company serves healthcare professionals and patients requiring continuous arrhythmia detection and diagnosis.

7 investors

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications. The company markets cells and disease models through its ioCells brand for use in biomedical research and therapeutic development.

7 investors

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.

7 investors

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets. The company combines genomics data analysis with therapeutic design to create more targeted treatments for cancer patients.

7 investors

Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology. The company serves laboratories, food brands, healthcare systems, and diagnostic organizations.

7 investors

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.

7 investors

Cofactor Genomics develops predictive diagnostics for cancer immunotherapy using RNA-expression models to characterize tumor microenvironments and predict patient response. The company serves oncology and precision medicine markets by enabling more accurate patient-to-therapy matching.

7 investors

Deepcell uses artificial intelligence and high-resolution imaging to analyze cell morphology for biological research and discovery. The company serves scientists and life science researchers across multiple biological domains.

7 investors

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.

7 investors

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

7 investors

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders. Founded in 2019, it focuses on the neuroscience area to treat central nervous system conditions.

7 investors

Enso Data provides AI-powered analysis of physiological waveforms, particularly sleep studies, to enable clinical diagnosis and patient monitoring. The platform serves clinicians in sleep medicine and related specialties by automating interpretation of medical signals to support proactive patient intervention.

7 investors

EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair. The company translates tissue engineering research into therapeutic products for orthopedic and surgical applications.

7 investors

Eyebot develops technology solutions for vision care, serving retailers, patients, and eye doctors to improve vision care delivery and access.

7 investors

Fellow is a high-complexity mail-in semen analysis lab operating in the U.S., offering a clinically validated diagnostic-grade mail-in semen test that accounts for sample degradation over time. It serves urology and fertility clinics and is developing seminal-fluid-based diagnostics, including research into cell-free DNA and prostate cancer biomarkers.

7 investors

Flatiron Health combines AI-powered technology and clinical expertise with real-world oncology data to help healthcare providers and life science organizations improve cancer care and research. The company operates a global oncology platform serving community oncologists and research institutions across the US, UK, Germany, and Japan.

7 investors

Flywheel provides a platform for organizing, managing, and sharing medical imaging data. The company serves pharmaceutical companies, medical device manufacturers, AI developers, and academic medical centers to accelerate clinical trials, advance AI development, and streamline research workflows.

7 investors

Gallant develops regenerative medicine therapies for veterinary care, bringing treatments from laboratory research into clinical practice for pets.

7 investors

7 investors

Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials. The company targets patients with heart failure caused by conditions such as myocardial infarction, with reference markets in Japan and the US.

7 investors

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

7 investors

Infiuss Health operates a decentralized clinical research platform that connects pharmaceutical sponsors with patient participants, physicians, and hospitals to conduct remote or hybrid clinical trials. The platform aims to accelerate drug development by diversifying participant cohorts and streamlining the recruitment and management of clinical studies.

7 investors